Streetbeat News

Analyst Ratings

SWAV

Morgan Stanley has upgraded ShockWave Medical's stock from Equal-Weight to Overweight and raised its price target from $291 to $335. This has resulted in the shares of ShockWave Medical trading higher.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 2:01 pm

INTA

Analysts have provided bullish ratings for Intapp (NASDAQ:INTA) within the last quarter, with an average price target of $48.5, a high of $55.00, and a low of $42.00. The average price target has increased by 26.66% over the past month.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 2:00 pm

NFLX

Morgan Stanley analyst Benjamin Swinburne has maintained an Equal-Weight rating on Netflix (NASDAQ:NFLX) and raised the price target from $350 to $450.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:59 pm

MCO

Morgan Stanley analyst Toni Kaplan has maintained an Equal-Weight rating on Moody's (NYSE:MCO) and raised the price target from $300 to $323.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:58 pm

LEVI

Morgan Stanley analyst Kimberly Greenberger has maintained an Equal-Weight rating on Levi Strauss (NYSE:LEVI) and lowered the price target from $16 to $15.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:56 pm

FTNT

Morgan Stanley analyst Hamza Fodderwala maintains an Overweight rating on Fortinet (NASDAQ:FTNT) and raises the price target from $77 to $84.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:55 pm

INTA

BTIG analyst Matt VanVliet has initiated coverage on Intapp (NASDAQ:INTA) with a Buy rating and a price target of $55.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:54 pm

CAVA

William Blair analyst Sharon Zackfia has initiated coverage on Cava Group (NYSE:CAVA) with an Outperform rating.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:53 pm

BMY

SVB Leerink analyst David Risinger has initiated coverage on Bristol-Myers Squibb (NYSE:BMY) with a Market Perform rating and a price target of $66.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:48 pm

TARA

Guggenheim analyst Charles Zhu has assumed Protara Therapeutics (NASDAQ:TARA) with a Buy rating and set a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

July 10, 2023 | 1:47 pm